Photo of Amalya Sargsyan from IMMUNOC.ORG
Oct 25, 2023, 19:02
Amalya Sargsyan: ESMO23 – Advances in EGFR mutated NSCLC
Amalya Sargsyan, Research Fellow at
“ESMO23: Advances in EGFR mutated NSCLC!
MARIPOSA: Amivantamab/Lazertinib vs. Osimertinib
Promising results! In 1L EGFR-mutated NSCLC, Amivantamab + Lazertinib reduced disease progression risk by 30%. PFS: 23.7 vs. 16.6 months.
MARIPOSA2: Option to overcome Osimertinib resistance. Amivantamab+Chemo
HR 0.44! In 2L, PFSvs. Chemo alone: 8.3 vs. 4.2m. Impressive ORR (63%) vs. Chemo (36%). Boosted intracranial PFS.
Note: More AEs.
These findings signal Amivantamab as a significant advancement in NSCLC treatment, offering hope to patients.”
Source: Amalya Sargsyan/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 16:51
Nov 13, 2024, 16:49
Nov 13, 2024, 16:45
Nov 13, 2024, 16:25
Nov 13, 2024, 16:23
Nov 13, 2024, 16:08
Nov 13, 2024, 16:02
Nov 13, 2024, 15:56